NewAmsterdam Pharma Company N.V. (NAMS) Total liabilities 2022–2025
NewAmsterdam Pharma Company N.V. (NAMS) total liabilities at each fiscal year-end, per SEC filings.
$85.9MFY2025 · since FY2022: $48.4M → $85.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $85.9M | -19.9% |
| FY2024 | $107.1M | +82.5% |
| FY2023 | $58.7M | +21.2% |
| FY2022 | $48.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice